Genfit: H1 NP tops E30m

(CercleFinance.com) - The biotech firm's revenues reached E61.
2m in H1 2024 (vs. E15.4m in H1 2023). NB: cp 12.7%.

Almost all revenues are attributable to our license agreement and our transition services agreement ('TSA') with Ipsen, management says.

Operating expenses amounted to E30m in H1 2024 (vs. E34.7m in H1 2023).

The decrease in operating expenses is mainly due to R&D costs, which amounted to E19m in H1 2024, compared with E25.6m in H1 2023, the group says.

H1 2024 posted net profit of E30.3m, compared with a net loss of E20.9m in H1 2023.

At 30 June 2024, Genfit had E61.6m in cash and cash equivalent (E77.8m at 31 December 2023).


Copyright (c) 2024 CercleFinance.com. All rights reserved.